Trial · NCT05630612
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
NCT05630612, Phase 2, Active not recruiting, University of Edinburgh
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC). Trials, record NCT05630612. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05630612
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
- NCT number
- NCT05630612
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 32 participants, actual
- Lead sponsor
- University of Edinburgh
- Conditions
- ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases
- Interventions
- Sparsentan
- First posted
- 2022-11-29
- Last updated
- 2026-08-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Forearm blood flow | Comparing baseline to after 6 weeks of intervention. | Change from baseline to week 6 in acetylcholine-mediated forearm blood flow vasodilatation |
| Secondary | Fibrinolytic capacity | Comparing baseline to after 6 weeks of intervention. | Plasma concentration of tissue plasminogen activator in response to bradykinin will be assessed before and after 6 weeks of intervention. Both tPA activity (in IU/ml) and tPA antigen (in ng/mL) will be assessed. |
| Secondary | Blood pressure | Comparing baseline to after 3 and 6 weeks of treatment. | Change from baseline 24h blood pressure and office blood pressure to after 3 and 6 weeks of treatment. We will assess systolic and diastolic blood pressure values as well as mean arterial pressure in mmHg. |
| Secondary | Arterial stiffness | Comparing baseline to after 3 and 6 weeks of treatment. | Change from baseline arterial stiffness to after 3 and 6 weeks of treatment. We will use a high fidelity micromanometer connected to a Sphygmocor device to measure pulse wave velocity in metres/second and augmentation index corrected for a heart rate of 75bpm measured in percentage. |
| Secondary | Systemic haemodynamics | Comparing baseline to after 3 and 6 weeks of treatment. | Change from baseline measures of systemic haemodynamics to after 3 and 6 weeks of treatment. We will use a BioZ diagnostics machine produced by CardioDynamics. This machine uses electrodes placed on the thorax and neck to automatically measure the following parameters of the heart beat cycle. Heart rate in beats/minute Stroke volume in mL/beat Stroke index in mL/beat/metre squared Cardiac output in L/min Cardiac Index in L/min/metre squared Systemic vascular resistance in dyne sec cm-5 Systemic vascular resistance index in dyne sec cm-5 metre squared Systolic time ratio index in sec-1 Thoracic fluid content in kiloohm-1 |
| Secondary | Proteinuria | Comparing baseline to after 3 and 6 weeks of treatment. | Change from baseline measures of proteinuria to after 3 and 6 weeks of treatment. |
| Other | Optical Coherence Tomography (OCT) | Comparing baseline to after 3 and 6 weeks of treatment. | Change from baseline OCT measures to after 3 and 6 weeks of treatment. |
| Other | Fluorescence-activated cell sorting | Comparing baseline to after 6 weeks of treatment. | Change from Baseline peripheral blood cells (balance of inflammatory and anti-inflammatory cells) analyzed using flow cytometry to after 6 weeks of treatment. |
| Other | Endothelin-1 clearance | Comparing baseline to after 6 weeks of treatment. | Change from Baseline peripheral blood monocytes ability to clear endothelin-1 using fluorescence-activated cell sorting (FACS) to after 6 weeks of treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35998848 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05630612
GET https://conductscience.org/api/trials/v1/NCT05630612/registered